On September 8, 2020 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that Mr. Jed Latkin, Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Navidea Biopharmaceuticals, SEP 8, 2020, https://ir.navidea.com/news/detail/356/navidea-biopharmaceuticals-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference [SID1234564744]). The virtual conference will be held on September 14-16, 2020. Mr. Latkin will present on Wednesday, September 16 at 10:30 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Navidea’s presentation are below. For those who wish to listen to the live webcast, please use the following link: View Source." target="_blank" title="View Source." rel="nofollow">View Source The webcast will be archived on Navidea’s investor relations website, View Source for 90 days following the live presentation.

Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Wednesday, September 16, 2020
Time: 10:30 – 10:50 a.m. EDT
Location: Virtual Conference
Presentation Webcast Link: View Source